# Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

> **NCT01561456** · PHASE2 · COMPLETED · sponsor: **Axelar AB** · enrollment: 100 (actual)

## Conditions studied

- Non-small-cell Lung Cancer
- Squamous Cell Carcinoma
- Adenocarcinoma of the Lung

## Interventions

- **DRUG:** AXL1717
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01561456
- **Lead sponsor:** Axelar AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2013-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01561456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01561456, "Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01561456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*